FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891525318> ?p ?o ?g. }

• W2891525318 endingPage "5826" @default.
• W2891525318 startingPage "5821" @default.
• W2891525318 abstract "Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report Li-Jun Liang,1,2,* Yi-Xuan Wen,1,2,* You-You Xia,1,* Lei Wang,1 Jia-Yan Fei,1,2 Xiao-Dong Jiang1,2 1Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People’s Republic of China; 2Tumor Laboratory, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People’s Republic of China *These authors contributed equally to this work Abstract: The first-line treatment for metastatic esophageal squamous cell cancer (ESCC) is a platinum- or fluorouracil-based agent, followed by later treatment with taxanes or irinotecan. However, there is still no standard third-line treatment for patients with metastatic ESCC. We present a 62-year-old man initially diagnosed with locally advanced ESCC. After esophagectomy, the patient was administrated with six cycles of docetaxel and cisplatin combined with radiotherapy. After 8.0 months, computed tomography showed the left cervical lymph node metastasis. However, the metastatic lymph node was not significantly shrunk after locally palliative radiotherapy and the patient was intolerant of irinotecan as second-line systemic therapy. Then, the patient was rechallenged with six cycles of docetaxel combined with apatinib (an oral tyrosine kinase inhibitor to vascular endothelial growth factor receptor 2 [VEGFR2]), followed by single dose of apatinib as maintenance therapy. According to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard, partial response was achieved in this case after treating with docetaxel combined with apatinib. Now, the progression-free survival of this patient has been 7.5 months. After administrating with apatinib for 2 weeks, hypertension (grade III) was observed. Thus, the dose of apatinib was decreased from 850 to 500 mg and then the adverse effects were controllable and tolerable. In conclusion, apatinib with concurrent docetaxel provided potential efficacy as a salvage treatment for patients with metastatic ESCC. To our knowledge, this is the first case of ESCC who responded to apatinib combined with docetaxel. Keywords: metastatic esophageal cancer, apatinib, docetaxel, vascular endothelial growth factor receptor-2, anti-angiogenesis" @default.
• W2891525318 created "2018-09-27" @default.
• W2891525318 creator A5009405793 @default.
• W2891525318 creator A5014392392 @default.
• W2891525318 creator A5046691390 @default.
• W2891525318 creator A5068301710 @default.
• W2891525318 creator A5069618747 @default.
• W2891525318 creator A5076665531 @default.
• W2891525318 date "2018-09-01" @default.
• W2891525318 modified "2023-09-26" @default.
• W2891525318 title "Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report" @default.
• W2891525318 cites W1567205022 @default.
• W2891525318 cites W1816099873 @default.
• W2891525318 cites W1976830577 @default.
• W2891525318 cites W1981186476 @default.
• W2891525318 cites W1999464994 @default.
• W2891525318 cites W2024547990 @default.
• W2891525318 cites W2027298808 @default.
• W2891525318 cites W2042844347 @default.
• W2891525318 cites W2044720517 @default.
• W2891525318 cites W2056163905 @default.
• W2891525318 cites W2105968397 @default.
• W2891525318 cites W2111237964 @default.
• W2891525318 cites W2113935263 @default.
• W2891525318 cites W2116435502 @default.
• W2891525318 cites W2117692326 @default.
• W2891525318 cites W2135708639 @default.
• W2891525318 cites W2138098788 @default.
• W2891525318 cites W2145092426 @default.
• W2891525318 cites W2188096656 @default.
• W2891525318 cites W2272984102 @default.
• W2891525318 cites W2276228008 @default.
• W2891525318 cites W2293809486 @default.
• W2891525318 cites W2467735990 @default.
• W2891525318 cites W2744041187 @default.
• W2891525318 cites W2766366470 @default.
• W2891525318 cites W2771395225 @default.
• W2891525318 cites W2917837889 @default.
• W2891525318 cites W2980869324 @default.
• W2891525318 cites W86769172 @default.
• W2891525318 doi "https://doi.org/10.2147/ott.s174429" @default.
• W2891525318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6145360" @default.
• W2891525318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30271164" @default.
• W2891525318 hasPublicationYear "2018" @default.
• W2891525318 type Work @default.
• W2891525318 sameAs 2891525318 @default.
• W2891525318 citedByCount "7" @default.
• W2891525318 countsByYear W28915253182019 @default.
• W2891525318 countsByYear W28915253182020 @default.
• W2891525318 countsByYear W28915253182021 @default.
• W2891525318 crossrefType "journal-article" @default.
• W2891525318 hasAuthorship W2891525318A5009405793 @default.
• W2891525318 hasAuthorship W2891525318A5014392392 @default.
• W2891525318 hasAuthorship W2891525318A5046691390 @default.
• W2891525318 hasAuthorship W2891525318A5068301710 @default.
• W2891525318 hasAuthorship W2891525318A5069618747 @default.
• W2891525318 hasAuthorship W2891525318A5076665531 @default.
• W2891525318 hasBestOaLocation W28915253181 @default.
• W2891525318 hasConcept C121608353 @default.
• W2891525318 hasConcept C126322002 @default.
• W2891525318 hasConcept C126838900 @default.
• W2891525318 hasConcept C143998085 @default.
• W2891525318 hasConcept C2776694085 @default.
• W2891525318 hasConcept C2776713427 @default.
• W2891525318 hasConcept C2778203143 @default.
• W2891525318 hasConcept C2778239845 @default.
• W2891525318 hasConcept C2778822529 @default.
• W2891525318 hasConcept C2779742542 @default.
• W2891525318 hasConcept C2779984678 @default.
• W2891525318 hasConcept C2780259306 @default.
• W2891525318 hasConcept C2780668389 @default.
• W2891525318 hasConcept C2781190966 @default.
• W2891525318 hasConcept C509974204 @default.
• W2891525318 hasConcept C526805850 @default.
• W2891525318 hasConcept C71924100 @default.
• W2891525318 hasConceptScore W2891525318C121608353 @default.
• W2891525318 hasConceptScore W2891525318C126322002 @default.
• W2891525318 hasConceptScore W2891525318C126838900 @default.
• W2891525318 hasConceptScore W2891525318C143998085 @default.
• W2891525318 hasConceptScore W2891525318C2776694085 @default.
• W2891525318 hasConceptScore W2891525318C2776713427 @default.
• W2891525318 hasConceptScore W2891525318C2778203143 @default.
• W2891525318 hasConceptScore W2891525318C2778239845 @default.
• W2891525318 hasConceptScore W2891525318C2778822529 @default.
• W2891525318 hasConceptScore W2891525318C2779742542 @default.
• W2891525318 hasConceptScore W2891525318C2779984678 @default.
• W2891525318 hasConceptScore W2891525318C2780259306 @default.
• W2891525318 hasConceptScore W2891525318C2780668389 @default.
• W2891525318 hasConceptScore W2891525318C2781190966 @default.
• W2891525318 hasConceptScore W2891525318C509974204 @default.
• W2891525318 hasConceptScore W2891525318C526805850 @default.
• W2891525318 hasConceptScore W2891525318C71924100 @default.
• W2891525318 hasLocation W28915253181 @default.
• W2891525318 hasLocation W28915253182 @default.
• W2891525318 hasLocation W28915253183 @default.
• W2891525318 hasLocation W28915253184 @default.
• W2891525318 hasLocation W28915253185 @default.
• W2891525318 hasOpenAccess W2891525318 @default.

• next